A Phase 2 Study to Evaluate the Safety, Efficacy and PK o... | NCT05128942

NCT05128942

Status Module

Sponsor/Collaborators Module

Oversight Module

Description Module

Conditions Module

Design Module

Interventional Study Design

Biospecimen

No data available

No data is available for this block.

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Cohort 1: Age 11-17 Treatment with Tildacerfont	Experimental	50 mg daily for 12 consecutive weeks.	Drug: Tildacerfont
Cohort 2: Age 11-17 Treatment with Tildacerfont	Experimental	200 mg daily for 12 consecutive weeks.	Drug: Tildacerfont
Cohort 3: Age 2-10 Treatment with Tildacerfont	Experimental	50, 100, or 200 mg daily for 12 consecutive weeks.	Drug: Tildacerfont
Cohort 4: Age >/= 18 Treatment with Tildacerfont	Experimental	200 mg twice daily for 4 consecutive weeks.	Drug: Tildacerfont
Cohort 5: Age >/= 18 Treatment with Tildacerfont	Experimental	300 or 400 mg twice daily for 4 consecutive weeks.	Drug: Tildacerfont
Cohort 6: Age 11-17 Treatment with Tildacerfont	Experimental

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Tildacerfont	Drug	Oral tablet formulation taken once daily in combination with glucocorticoid therapy.	Cohort 1: Age 11-17 Treatment with Tildacerfont Cohort 2: Age 11-17 Treatment with Tildacerfont

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Number of Participants With Treatment-emergent Adverse Event (TEAE) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0	To evaluate safety of tildacerfont in participants with CAH as measured by number of subjects with adverse events following dosing by CTCAE version 5.0	12 weeks

Secondary Outcomes

Measure	Description	Time Frame
Proportion of Participants Who Achieve a Reduction in Androstenedione (A4) or Reduction in Glucocorticoid (GC) Dosing	To determine the efficacy of tildacerfont on disease control or reduction of GC use in participants with classic CAH as measured by number of subjects who achieve a reduction in A4 or reduction in GC dosing during treatment period	12 weeks

Eligibility Module

Contacts/Locations Module

Name	Affiliation	Role
Will Charlton, MD	Spruce Biosciences	Study Director

Facility	Status	City	State	ZIP	Country	Contacts
Spruce Study Site		Sacramento	California	95821	United States
Spruce Study Site

References Module

No data available

No data is available for this block.

IPD Sharing Statement Module

Results Section

Participant Flow Module

Arm/Group Information

ID	Title	Description
FG000	Cohort 1: Age 11-17 Treatment With Tildacerfont	50 mg daily for 12 consecutive weeks.
FG001	Cohort 2: Age 11-17 Treatment With Tildacerfont	200 mg daily for 12 consecutive weeks.

Baseline Characteristics Module

Outcome Measures Module

Adverse Events Module

More Info Module

Annotation Section

No data available

No data is available for this block.

Document Section

Large Document Module

Type	Includes Protocol	Includes SAP	Includes ICF	Document Label	Document Date	Document Uploaded Date	Document File Name
Prot	Yes	No	No	Study Protocol	Nov 30, 2023	Sep 2, 2025

Derived Section

Miscellaneous Info Module

Submission Tracking

Condition Browse Module

Intervention Browse Module

No data available

No data is available for this block.

Masking Info

200 mg twice daily for 4 consecutive weeks.

Cohort 3: Age 2-10 Treatment with Tildacerfont

Cohort 4: Age >/= 18 Treatment with Tildacerfont

Cohort 5: Age >/= 18 Treatment with Tildacerfont

Cohort 6: Age 11-17 Treatment with Tildacerfont

Cohort 7: Age 2-10 Treatment with Tildacerfont

Cohort 8: Age 11-17 Treatment with Tildacerfont

Cohort 9: Age 2-10 Treatment with Tildacerfont

Type of Units Analyzed

Arm/Group Information

ID	Title	Description
BG000	Cohort 1: Age 11-17 Treatment With Tildacerfont	50 mg daily for 12 consecutive weeks.
BG001	Cohort 2: Age 11-17 Treatment With Tildacerfont	200 mg daily for 12 consecutive weeks.
BG002	Cohort 3: Age 2-10 Treatment With Tildacerfont	50, 100, or 200 mg daily for 12 consecutive weeks.
BG003	Cohort 4: Treatment With Tildacerfont	200 mg twice daily for 4 consecutive weeks.
BG004	Cohort 5: Treatment With Tildacerfont	300 or 400 mg twice daily for 4 consecutive weeks.
BG005	Cohort 6: Treatment With Tildacerfont	200 mg twice daily for 4 consecutive weeks.
BG006	Cohort 7: Treatment With Tildacerfont	200 mg twice daily for 4 consecutive weeks.
BG007	Cohort 8: Treatment With Tildacerfont	300 or 400 mg twice daily for 4 consecutive weeks.
BG008	Total	Total of all reporting groups

Units	Counts
Participants	BG0007 BG0017 BG00218 BG0032 BG0046 BG0058 BG00612 BG0077 BG00867

Baseline Measures

Title

Description

Population Description

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Denominator Units Selected

Denominators

Classes

Age, Continuous

Mean

Standard Deviation

years

Title

Denominators

Categories

Title	Measurements
	BG00013.238± 1.688 BG00114.381± 2.539 BG0027.722± 2.3279 BG003

Sex: Female, Male

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Female	BG0007 BG0013 BG002

Ethnicity (NIH/OMB)

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Hispanic or Latino	BG0001 BG0012 BG002

Race

Count of Participants

Participants

Title

Denominators

Categories

Asian

Title	Measurements
	BG0000 BG0011 BG002

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Number of Participants With Treatment-emergent Adverse Event (TEAE) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0

To evaluate safety of tildacerfont in participants with CAH as measured by number of subjects with adverse events following dosing by CTCAE version 5.0

For Cohorts 5 and 8, the Statistical Analysis Plan pre-specified to analyze the data separately "per Cohort," without regard to dose.

Posted

Count of Participants

Participants

12 weeks

ID	Title	Description
OG000	Cohort 1: Age 11-17 Treatment With Tildacerfont	50 mg daily for 12 consecutive weeks.
OG001	Cohort 2: Age 11-17 Treatment With Tildacerfont	200 mg daily for 12 consecutive weeks.
OG002	Cohort 3: Age 2-10 Treatment With Tildacerfont	50, 100, or 200 mg daily for 12 consecutive weeks.
OG003	Cohort 4: Treatment With Tildacerfont	200 mg twice daily for 4 consecutive weeks.
OG004	Cohort 5: Treatment With Tildacerfont	300 or 400 mg twice daily for 4 consecutive weeks.
OG005	Cohort 6: Treatment With Tildacerfont	200 mg twice daily for 4 consecutive weeks.
OG006	Cohort 7: Treatment With Tildacerfont	200 mg twice daily for 4 consecutive weeks.
OG007	Cohort 8: Treatment With Tildacerfont	300 or 400 mg twice daily for 4 consecutive weeks.

Units	Counts
Participants	OG0007 OG0017 OG00218 OG003

Title

Denominators

Categories

Title	Measurements
	OG0004 OG0016 OG00218 OG003

Secondary

Proportion of Participants Who Achieve a Reduction in Androstenedione (A4) or Reduction in Glucocorticoid (GC) Dosing

To determine the efficacy of tildacerfont on disease control or reduction of GC use in participants with classic CAH as measured by number of subjects who achieve a reduction in A4 or reduction in GC dosing during treatment period

For Cohorts 5 and 8, the Statistical Analysis Plan pre-specified to analyze the data separately "per Cohort," without regard to dose.

Posted

Count of Participants

Participants

12 weeks

ID	Title	Description
OG000	Cohort 1: Age 11-17 Treatment With Tildacerfont	50 mg daily for 12 consecutive weeks.
OG001	Cohort 2: Age 11-17 Treatment With Tildacerfont	200 mg daily for 12 consecutive weeks.
OG002	Cohort 3: Age 2-10 Treatment With Tildacerfont	50, 100, or 200 mg daily for 12 consecutive weeks.
OG003	Cohort 4: Treatment With Tildacerfont	200 mg twice daily for 4 consecutive weeks.

Secondary

Proportion of Participants With Elevated Baseline A4 Who Achieve a Reduction in A4

To determine the efficacy of tildacerfont on disease control in participants with classic CAH measured by the number of participants with elevated baseline A4 who achieve reduction in A4 at week 4

For Cohorts 5 and 8, the Statistical Analysis Plan pre-specified to analyze the data separately "per Cohort," without regard to dose.

Posted

Count of Participants

Participants

4 weeks

ID	Title	Description
OG000	Cohort 1: Age 11-17 Treatment With Tildacerfont	50 mg daily for 12 consecutive weeks.
OG001	Cohort 2: Age 11-17 Treatment With Tildacerfont	200 mg daily for 12 consecutive weeks.
OG002	Cohort 3: Age 2-10 Treatment With Tildacerfont	50, 100, or 200 mg daily for 12 consecutive weeks.
OG003	Cohort 4: Treatment With Tildacerfont	200 mg twice daily for 4 consecutive weeks.

Secondary

Proportion of Participants With Elevated Baseline A4 Who Achieve a Reduction in A4 Who Achieve A4 Normalization

To determine the efficacy of tildacerfont on disease control in participants with classic CAH measured by the number of participants with elevated baseline A4 who achieve reduction in A4 at week 4 or week 12

For Cohorts 5 and 8, the Statistical Analysis Plan pre-specified to analyze the data separately "per Cohort," without regard to dose.

Posted

Count of Participants

Participants

4 weeks or 12 weeks

ID	Title	Description
OG000	Cohort 1: Age 11-17 Treatment With Tildacerfont	50 mg daily for 12 consecutive weeks.
OG001	Cohort 2: Age 11-17 Treatment With Tildacerfont	200 mg daily for 12 consecutive weeks.
OG002	Cohort 3: Age 2-10 Treatment With Tildacerfont	50, 100, or 200 mg daily for 12 consecutive weeks.
OG003	Cohort 4: Treatment With Tildacerfont	200 mg twice daily for 4 consecutive weeks.

Arm/Groups

ID	Title	Description	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Cohort 1: Age 11-17 Treatment With Tildacerfont	50 mg daily for 12 consecutive weeks.	7	0	7	4	7
EG001	Cohort 2: Age 11-17 Treatment With Tildacerfont	200 mg daily for 12 consecutive weeks.	7	1	7	6	7
EG002	Cohort 3: Age 2-10 Treatment With Tildacerfont	50, 100, or 200 mg daily for 12 consecutive weeks.	18	1	18	18	18
EG003	Cohort 4: Treatment With Tildacerfont	200 mg twice daily for 4 consecutive weeks.	2	0	2	2	2
EG004	Cohort 5: 300 mg Tildacerfont	300 mg twice daily for 4 consecutive weeks.	1	0	1	0	1
EG005	Cohort 5: 400 mg Tildacerfont	400 mg twice daily for 4 consecutive weeks.	5	0	5	3	5
EG006	Cohort 6: Treatment With Tildacerfont	200 mg twice daily for 4 consecutive weeks.	8	0	8	8	8
EG007	Cohort 7: Treatment With Tildacerfont	200 mg twice daily for 4 consecutive weeks.	12	1	12	12	12
EG008	Cohort 8: 300 mg Tildacerfont	300 mg twice daily for 4 consecutive weeks.	3	0	3	2	3
EG009	Cohort 8: 400 mg Tildacerfont	400 mg twice daily for 4 consecutive weeks.	4	0	4	3	4

Serious Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Notes	Statistical Information
Adrenal insufficiency	Endocrine disorders		Systematic Assessment		EG0000 affected7 at risk EG0011 affected7 at risk EG0020 affected18 at risk EG0030 affected2 at risk EG0040 affected1 at risk EG0055 at risk EG0060 affected8 at risk EG0071 affected12 at risk EG0080 affected3 at risk EG0094 at risk
Gastroenteritis	Gastrointestinal disorders		Systematic Assessment		EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003

Other Adverse Events

Term	Organ System	Assessment Type	Statistical Information
Neutropenia	Blood and lymphatic system disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG0030 affected2 at risk EG0040 affected1 at risk EG0050 affected5 at risk EG0060 affected8 at risk EG0070 affected12 at risk EG0080 affected3 at risk EG0090 affected4 at risk
Ear pain	Ear and labyrinth disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Adrenal insufficiency	Endocrine disorders	Systematic Assessment	EG0000 affected7 at risk EG0011 affected7 at risk EG0020 affected18 at risk EG003
Autoimmune thyroiditis	Endocrine disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Hypothyroidism	Endocrine disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Precocious puberty	Endocrine disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Vision blurred	Eye disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Eye irritation	Eye disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Vomiting	Gastrointestinal disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0027 affected18 at risk EG003
Nausea	Gastrointestinal disorders	Systematic Assessment	EG0001 affected7 at risk EG0010 affected7 at risk EG0025 affected18 at risk EG003
Abdominal pain upper	Gastrointestinal disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Constipation	Gastrointestinal disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Gastroesophageal reflux disease	Gastrointestinal disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Abdominal discomfort	Gastrointestinal disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Adrenogenital syndrome	Congenital, familial and genetic disorders	Systematic Assessment	EG0000 affected7 at risk EG0011 affected7 at risk EG0020 affected18 at risk EG003
Faece pale	Gastrointestinal disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Lip ulceration	Gastrointestinal disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Diarrhea	Gastrointestinal disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Dyspepsia	Gastrointestinal disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Pyrexia	General disorders	Systematic Assessment	EG0001 affected7 at risk EG0010 affected7 at risk EG0029 affected18 at risk EG003
Fatigue	General disorders	Systematic Assessment	EG0002 affected7 at risk EG0011 affected7 at risk EG0022 affected18 at risk EG003
Influenza like illness	General disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0022 affected18 at risk EG003
Chills	General disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Cyst	General disorders	Systematic Assessment	EG0001 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Medical device pain	General disorders	Systematic Assessment	EG0000 affected7 at risk EG0011 affected7 at risk EG0020 affected18 at risk EG003
Pain	General disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Seasonal allergy	Immune system disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Hypersensitivity	Immune system disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Nasopharyngitis	Infections and infestations	Systematic Assessment	EG0001 affected7 at risk EG0010 affected7 at risk EG0026 affected18 at risk EG003
Upper respiratory tract infection	Infections and infestations	Systematic Assessment	EG0001 affected7 at risk EG0010 affected7 at risk EG0025 affected18 at risk EG003
Gastroenteritis viral	Infections and infestations	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0025 affected18 at risk EG003
Influenza	Infections and infestations	Systematic Assessment	EG0000 affected7 at risk EG0012 affected7 at risk EG0024 affected18 at risk EG003
Otitis media	Infections and infestations	Systematic Assessment	EG0002 affected7 at risk EG0010 affected7 at risk EG0022 affected18 at risk EG003
Pharyngitis	Infections and infestations	Systematic Assessment	EG0001 affected7 at risk EG0010 affected7 at risk EG0022 affected18 at risk EG003
Pharyngitis streptococcal	Infections and infestations	Systematic Assessment	EG0000 affected7 at risk EG0011 affected7 at risk EG0022 affected18 at risk EG003
COVID-19	Infections and infestations	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0023 affected18 at risk EG003
Gastroenteritis	Infections and infestations	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Viral upper respiratory tract infection	Infections and infestations	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Bronchitis	Infections and infestations	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Impetigo	Infections and infestations	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Sinusitis	Infections and infestations	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Appendicitis	Infections and infestations	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Beta hemolytic streptococcal infection	Infections and infestations	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Conjunctivitis bacterial	Infections and infestations	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Erythema infectiosum	Infections and infestations	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Otitis externa	Infections and infestations	Systematic Assessment	EG0001 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Respiratory syncytial virus infection	Infections and infestations	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Urethritis	Infections and infestations	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Urinary tract infection	Infections and infestations	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Viral infection	Infections and infestations	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Viral rhinitis	Infections and infestations	Systematic Assessment	EG0000 affected7 at risk EG0011 affected7 at risk EG0020 affected18 at risk EG003
Ear infection	Infections and infestations	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Concussion	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected7 at risk EG0012 affected7 at risk EG0020 affected18 at risk EG003
Ligament sprain	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected7 at risk EG0011 affected7 at risk EG0021 affected18 at risk EG003
Arthropod bite	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Arthropod sting	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Exposure to toxic agent	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Limb fracture	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Skin abrasion	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Wrist fracture	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Neck injury	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
SARS-CoV-2 test positive	Investigations	Systematic Assessment	EG0000 affected7 at risk EG0011 affected7 at risk EG0021 affected18 at risk EG003
Liver function test abnormal	Investigations	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
17-hydroxyprogesterone increased	Investigations	Systematic Assessment	EG0000 affected7 at risk EG0011 affected7 at risk EG0020 affected18 at risk EG003
Blood androstenedione increased	Investigations	Systematic Assessment	EG0000 affected7 at risk EG0011 affected7 at risk EG0020 affected18 at risk EG003
Blood urine present	Investigations	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Hemoglobin decreased	Investigations	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Urine output increased	Investigations	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Weight decreased	Investigations	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Weight increased	Investigations	Systematic Assessment	EG0000 affected7 at risk EG0011 affected7 at risk EG0020 affected18 at risk EG003
Increased appetite	Metabolism and nutrition disorders	Systematic Assessment	EG0000 affected7 at risk EG0011 affected7 at risk EG0020 affected18 at risk EG003
Dehydration	Metabolism and nutrition disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Food craving	Metabolism and nutrition disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Pain in extremity	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected7 at risk EG0011 affected7 at risk EG0021 affected18 at risk EG003
Growing pains	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Muscular weakness	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Myalgia	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected7 at risk EG0011 affected7 at risk EG0020 affected18 at risk EG003
Headache	Nervous system disorders	Systematic Assessment	EG0002 affected7 at risk EG0011 affected7 at risk EG0027 affected18 at risk EG003
Presyncope	Nervous system disorders	Systematic Assessment	EG0000 affected7 at risk EG0011 affected7 at risk EG0020 affected18 at risk EG003
Dizziness	Nervous system disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Dysarthria	Nervous system disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Hemiparesis	Nervous system disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Migraine	Nervous system disorders	Systematic Assessment	EG0000 affected7 at risk EG0011 affected7 at risk EG0020 affected18 at risk EG003
Parosmia	Nervous system disorders	Systematic Assessment	EG0000 affected7 at risk EG0011 affected7 at risk EG0020 affected18 at risk EG003
Syncope	Nervous system disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Anxiety	Psychiatric disorders	Systematic Assessment	EG0001 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Attention deficit hyperactivity disorder	Psychiatric disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Autism spectrum disorder	Psychiatric disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Insomnia	Psychiatric disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Mood altered	Psychiatric disorders	Systematic Assessment	EG0000 affected7 at risk EG0011 affected7 at risk EG0020 affected18 at risk EG003
Mood swings	Psychiatric disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Pollakiuria	Renal and urinary disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Balanoposthitis	Reproductive system and breast disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Gynaecomastia	Reproductive system and breast disorders	Systematic Assessment	EG0000 affected7 at risk EG0011 affected7 at risk EG0020 affected18 at risk EG003
Heavy menstrual bleeding	Reproductive system and breast disorders	Systematic Assessment	EG0000 affected7 at risk EG0011 affected7 at risk EG0020 affected18 at risk EG003
Oligomenorrhoea	Reproductive system and breast disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Cough	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 affected7 at risk EG0010 affected7 at risk EG0023 affected18 at risk EG003
Oropharyngeal pain	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0023 affected18 at risk EG003
Rhinorrhoea	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0022 affected18 at risk EG003
Nasal congestion	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Allergic cough	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Aphonia	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Rash	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0022 affected18 at risk EG003
Acanthosis	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Acanthosis nigricans	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Acne	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 affected7 at risk EG0011 affected7 at risk EG0020 affected18 at risk EG003
Alopecia	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Blister	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Dermatitis allergic	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Eczema	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003
Pruritus	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Dermatitis contact	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Rash papular	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Skin exfoliation	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0020 affected18 at risk EG003
Abdominal Pain	Gastrointestinal disorders	Systematic Assessment	EG0000 affected7 at risk EG0010 affected7 at risk EG0021 affected18 at risk EG003

First MCP Posted Date

ID	Term
D000312	Adrenal Hyperplasia, Congenital
D000307	Adrenal Gland Diseases

Ancestor Terms

ID	Term
D047808	Adrenogenital Syndrome
D012734	Disorders of Sex Development
D014564	Urogenital Abnormalities
D052776	Female Urogenital Diseases
D005261	Female Urogenital Diseases and Pregnancy Complications
D000091642	Urogenital Diseases
D052801	Male Urogenital Diseases
D000013	Congenital Abnormalities
D009358	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
D030342	Genetic Diseases, Inborn
D043202	Steroid Metabolism, Inborn Errors
D008661	Metabolism, Inborn Errors
D008659	Metabolic Diseases
D009750	Nutritional and Metabolic Diseases
D004700	Endocrine System Diseases
D006058	Gonadal Disorders

BG00426.333± 8.2635

BG00514.354± 2.0792

BG00715.214± 1.7192

BG00812.604± 6.7977

EG0040 affected1 at risk

EG0060 affected8 at risk

EG0070 affected12 at risk

EG0080 affected3 at risk

EG0040 affected1 at risk

EG0050 affected5 at risk

EG0060 affected8 at risk

EG0071 affected12 at risk

EG0080 affected3 at risk

EG0090 affected4 at risk

EG0040 affected1 at risk

EG0050 affected5 at risk

EG0060 affected8 at risk

EG0071 affected12 at risk

EG0080 affected3 at risk

EG0090 affected4 at risk

EG0040 affected1 at risk

EG0050 affected5 at risk

EG0061 affected8 at risk

EG0070 affected12 at risk

EG0080 affected3 at risk

EG0090 affected4 at risk

EG0040 affected1 at risk

EG0050 affected5 at risk

EG0060 affected8 at risk

EG0071 affected12 at risk

EG0080 affected3 at risk

EG0090 affected4 at risk

EG0040 affected1 at risk

EG0050 affected5 at risk

EG0060 affected8 at risk

EG0070 affected12 at risk

EG0080 affected3 at risk

EG0090 affected4 at risk

EG0040 affected1 at risk

EG0050 affected5 at risk

EG0060 affected8 at risk

EG0070 affected12 at risk

EG0080 affected3 at risk

EG0090 affected4 at risk

EG0040 affected1 at risk

EG0050 affected5 at risk

EG0060 affected8 at risk

EG0070 affected12 at risk

EG0080 affected3 at risk

EG0090 affected4 at risk

EG0040 affected1 at risk

EG0051 affected5 at risk

EG0061 affected8 at risk

EG0075 affected12 at risk

EG0080 affected3 at risk

EG0092 affected4 at risk

EG0040 affected1 at risk

EG0051 affected5 at risk

EG0061 affected8 at risk

EG0070 affected12 at risk

EG0080 affected3 at risk

EG0090 affected4 at risk

EG0040 affected1 at risk

EG0050 affected5 at risk

EG0060 affected8 at risk

EG0071 affected12 at risk

EG0080 affected3 at risk

EG0090 affected4 at risk

EG0040 affected1 at risk

EG0050 affected5 at risk

EG0060 affected8 at risk

EG0070 affected12 at risk

EG0080 affected3 at risk

EG0091 affected4 at risk

EG0040 affected1 at risk

EG0050 affected5 at risk

EG0060 affected8 at risk

EG0071 affected12 at risk

EG0080 affected3 at risk

EG0090 affected4 at risk

EG0040 affected1 at risk

EG0050 affected5 at risk

EG0060 affected8 at risk

EG0070 affected12 at risk

EG0080 affected3 at risk

EG0090 affected4 at risk

EG0040 affected1 at risk

EG0050 affected5 at risk

EG0060 affected8 at risk

EG0070 affected12 at risk

EG0080 affected3 at risk

EG0090 affected4 at risk

EG0040 affected1 at risk

EG0050 affected5 at risk

EG0060 affected8 at risk

EG0071 affected12 at risk

EG0080 affected3 at risk

EG0090 affected4 at risk

EG0040 affected1 at risk

EG0050 affected5 at risk

EG0060 affected8 at risk

EG0071 affected12 at risk

EG0080 affected3 at risk

EG0090 affected4 at risk

EG0040 affected1 at risk

EG0050 affected5 at risk

EG0060 affected8 at risk

EG0070 affected12 at risk

EG0080 affected3 at risk

EG0090 affected4 at risk

EG0040 affected1 at risk

EG0051 affected5 at risk

EG0060 affected8 at risk

EG0070 affected12 at risk

EG0080 affected3 at risk

EG0090 affected4 at risk

EG0040 affected1 at risk

EG0050 affected5 at risk

EG0061 affected8 at risk

EG0074 affected12 at risk

EG0080 affected3 at risk

EG0090 affected4 at risk

EG0040 affected1 at risk

EG0050 affected5 at risk

EG0060 affected8 at risk

EG0070 affected12 at risk

EG0080 affected3 at risk

EG0090 affected4 at risk

EG0040 affected1 at risk

EG0050 affected5 at risk

EG0060 affected8 at risk

EG0070 affected12 at risk

EG0080 affected3 at risk

EG0090 affected4 at risk

EG0040 affected1 at risk

EG0050 affected5 at risk

EG0060 affected8 at risk

EG0070 affected12 at risk

EG0080 affected3 at risk

EG0090 affected4 at risk

EG0040 affected1 at risk

EG0050 affected5 at risk

EG0060 affected8 at risk

EG0070 affected12 at risk

EG0080 affected3 at risk